+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures



Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures



Cochrane Database of Systematic Reviews 2001(4): Cd002217



Worldwide, phenytoin and phenobarbitone are commonly used antiepileptic drugs. They are more likely to be used in the developing world than the developed world, primarily because they are inexpensive. The aim of this review is to summarise data from existing trials comparing phenytoin and phenobarbitone. To review the effects of phenobarbitone compared to phenytoin when used as monotherapy in patients with partial onset seizures or generalized tonic-clonic seizures with or without other generalized seizure types. Our search strategy has included: a) MEDLINE 1966 to 1998, b) the controlled trials register of the Cochrane Library, c) hand-searching relevant journals, d) the pharmaceutical industry, e) researchers in the field. Randomized controlled trials in children or adults with partial onset seizures or generalized onset tonic-clonic seizures. Trials must have included a comparison of phenobarbitone monotherapy with phenytoin monotherapy. This was an individual patient data review. Outcomes were time to a) withdrawal of allocated treatment, b) 12 month remission, and c) first seizure post randomization. Data were analysed using a stratified logrank analysis with results expressed as hazard ratios (HR) and 95% confidence intervals (95% CI), where a HR>1 indicates an event is more likely to occur earlier on phenobarbitone than phenytoin. To date, data have been obtained for four of ten studies meeting the inclusion criteria, amounting to 599 patients, or approximately 65% of the potential data. The main overall results (HR, 95% CI) were: a) time to treatment withdrawal 1.62 (1.22 to 2.14), b) time to 12 month remission 0.93 (0.70 to 1.23), c) time to first seizure 0.84 (0.68 to 1.05). These results indicate a statistically significant clinical advantage for phenytoin in terms of treatment withdrawal and a non-significant advantage in terms of 12 month remission. Results for time to first seizure suggest a non-significant clinical advantage for phenobarbitone. The results of this review favour phenytoin over phenobarbitone, as phenobarbitone was significantly more likely to be withdrawn than phenytoin. Given that no significant differences for seizure outcomes were found, the higher withdrawal rate with phenobarbitone may be due to side effects.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046973200

Download citation: RISBibTeXText

PMID: 11687150

DOI: 10.1002/14651858.cd002217


Related references

Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. Cochrane Database of Systematic Reviews 2013(1): Cd002217, 2013

Phenytoin versus valproate monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database of Systematic Reviews 2001(4): Cd001769, 2001

Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures. Cochrane Database of Systematic Reviews 2013(8): Cd001769, 2013

Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures: an individual participant data review. Cochrane Database of Systematic Reviews 4: Cd001769, 2016

Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures. Expert Review of Neurotherapeutics 19(1): 5, 2019

Clinical efficacy of perampanel for partial-onset and primary generalized tonic-clonic seizures. Neuropsychiatric Disease and Treatment 12: 1215-1220, 2016

Topiramate as first-line therapy in epilepsy characterized by partial-onset or generalized tonic-clonic seizures. Annals of Neurology 54(Suppl 7): S135, 2003

Topiramate as first-line therapy in newly diagnosed epilepsy characterized by partial-onset or primary generalized tonic-clonic seizures. Epilepsia 44(Suppl. 9): 273, 2003

Budget impact of perampanel as adjunctive treatment of uncontrolled partial-onset and primary generalized tonic-clonic seizures in the United States. Epilepsy and Behavior 68: 196-202, 2017

HIPDM single photon emission computed tomography brain imaging in partial onset secondarily generalized tonic-clonic seizures. Epilepsia 28(3): 305-311, 1987

Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. New England Journal of Medicine 313(3): 145-151, 1985

Potentially high-risk cardiac arrhythmias with focal to bilateral tonic-clonic seizures and generalized tonic-clonic seizures are associated with the duration of periictal hypoxemia. Epilepsia 58(12): 2164-2171, 2017

Clobazam monotherapy for partial-onset or generalized-onset seizures. Cochrane Database of Systematic Reviews 2014(10): Cd009258, 2014

Natural History and Prognosis of Partial Seizures Evolving to Secondarily Generalized Tonic-Clonic Seizures. Psychiatry and Clinical Neurosciences 38(3): 277-281, 1984

Carbamazepine vs phenytoin in the treatment of epileptic seizures generalized from onset secondarily generalized and partial epileptic seizures with motor symptoms. Epilepsia: 294, 1977